Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 20 05 2019
accepted: 04 09 2019
pubmed: 26 9 2019
medline: 6 8 2021
entrez: 26 9 2019
Statut: ppublish

Résumé

For patients with prostate cancer, validated and reliable instruments are essential for measuring patient-reported outcomes. The aim of this study was to validate the German version of the widely established Expanded Prostate Cancer Index Composite with 26 items (EPIC-26). A German translation of the original questionnaire was tested in 3094 patients with localized or locally advanced (any T, any N and M0) prostate cancer with treatment intent (including radical prostatectomy, brachytherapy, active surveillance, watchful waiting). They completed the EPIC-26 questionnaire before treatment. A total of 521 of them also completed a questionnaire 12 months afterward. Internal consistency, sensitivity to change, and construct validity were assessed. The internal consistency of all domains was sufficient (Cronbach's alpha between 0.64 and 0.93). Item-to-scale correlation coefficients showed acceptable associations between items and their domain score (all > 0.30), with the lowest scores for "bloody stools" (r = 0.37) and "breast problems" (r = 0.32). Confirmatory and exploratory factor analysis confirmed the five-dimension structure of the EPIC-26 (comparative fit index 0.95). Psychometric evaluation suggests that the German version of the EPIC-26 is a well-constructed instrument for measuring patient-reported health-related symptoms in patients with prostate cancer.

Identifiants

pubmed: 31552467
doi: 10.1007/s00345-019-02949-7
pii: 10.1007/s00345-019-02949-7
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

11-25

Références

Zentrum für Krebsregisterdaten and Gesellschaft der epidemiologischen Krebsregister in Deutschland (2017) Krebs in Deutschland für 2013/2014. Robert Koch-Institut, Berlin
Trama A et al (2015) Survival of male genital cancers (prostate, testis and penis) in Europe 1999-2007: results from the EUROCARE-5 study. Eur J Cancer 51(15):2206–2216
doi: 10.1016/j.ejca.2015.07.027
Litwin MS et al (1995) Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273(2):129–135
doi: 10.1001/jama.1995.03520260051032
Madalinska JB et al (2001) Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol 19(6):1619–1628
doi: 10.1200/JCO.2001.19.6.1619
Sanda MG et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261
doi: 10.1056/NEJMoa074311
Wei JT et al (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56(6):899–905
doi: 10.1016/S0090-4295(00)00858-X
Szymanski KM et al (2010) Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76(5):1245–1250
doi: 10.1016/j.urology.2010.01.027
Schmidt S et al (2014) Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments. Qual Life Res 23(8):2169–2181
doi: 10.1007/s11136-014-0678-8
Lam WWT et al (2017) Psychometric assessment of the Chinese version of the abbreviated expanded prostate cancer index composite (EPIC-26) and the clinical practice version (EPIC-CP) in chinese men with prostate cancer. J Pain Symptom Manage 53(6):1085–1090
doi: 10.1016/j.jpainsymman.2017.02.010
Fossa SD et al (2016) Psychometric testing of the Norwegian version of the expanded prostate cancer index composite 26-item version (EPIC-26). Scand J Urol 50(4):280–285
doi: 10.3109/21681805.2016.1163617
Vigneault E et al (2017) Validation of the French-Canadian version of the expanded prostate cancer index composite (EPIC) in a French-Canadian population. Can Urol Assoc J 11(12):404–410
doi: 10.5489/cuaj.4428
Beyer B et al (2015) “Expanded prostate cancer index composite” (EPIC-26): Funktionelles Behandlungsergebnis bei Patienten mit lokalisiertem Prostatakarzinom. Urologe A 54(11):1591–1595
doi: 10.1007/s00120-015-3922-0
Umbehr MH et al (2018) The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation. Health Qual Life Outcomes 16(1):36
doi: 10.1186/s12955-018-0859-1
Evans SM et al (2017) Cohort profile: the TrueNTH Global Registry: an international registry to monitor and improve localised prostate cancer health outcomes. BMJ Open 7(11):e017006
doi: 10.1136/bmjopen-2017-017006
Martin NE et al (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67(3):460–467
doi: 10.1016/j.eururo.2014.08.075
ICHOM ( 2017) Localized prostate cancer data collection reference guide. https://ichom.org/files/medical-conditions/localized-prostate-cancer/localized-prostate-cancer-reference-guide.pdf . Accessed 23 Sep 2019
Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334
doi: 10.1007/BF02310555
Cohen J (1988) Statistical power analysis for the behavioral sciences. N.J.L. Erlbaum Associates, Hillsdale
Nunnally CJ, Bernstein I (1994) Psychometric Theory. McGraw-Hill, New York
Reeve Bryce B et al (2018) Symptom and function profiles of men with localized prostate cancer. Cancer 124(13):2832–2840
doi: 10.1002/cncr.31401
Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
German Guideline Program in Oncology (2018) ed. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 5.0, 1. Aktualisierung, AWMF-Registernummer: 043/022OL
Wei J, Dunn R, Litwin M, Sandler H, and Sanda M (2000) Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56:899–905

Auteurs

Nora Tabea Sibert (NT)

German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany. sibert@krebsgesellschaft.de.

Sebastian Dieng (S)

OnkoZert, Neu-Ulm, Germany.

Alisa Oesterle (A)

OnkoZert, Neu-Ulm, Germany.

Günter Feick (G)

Federal Association of German Prostate Cancer Patient Support Groups, Bonn, Germany.

Günther Carl (G)

Help for Prostate Cancer Patients (Förderverein Hilfe bei Prostatakrebs e.V.-FHbP), Tornesch, Germany.

Thomas Steiner (T)

Helios Klinikum Erfurt, Erfurt, Germany.

Jörg Minner (J)

Hegau-Bodensee-Klinikum Singen, Singen, Germany.

Florian Roghmann (F)

Marien Hospital, Ruhr-University Bochum, Herne, Germany.

Björn Kaftan (B)

Städtisches Klinikum Lüneburg, Lüneburg, Germany.

Friedemann Zengerling (F)

Universitätsklinikum Ulm, Ulm, Germany.

Andreas Hinkel (A)

Franziskus Hospital, Bielefeld, Germany.

Burkhard Beyer (B)

Martini-Klinik Prostate Cancer Center Hamburg, Hamburg, Germany.

Axel Heidenreich (A)

Universitätsklinikum Köln, Cologne, Germany.

Nina Harke (N)

University Hospital Essen, Essen, Germany.

Bernhard Brehmer (B)

Diaconal Hospital of Schwäbisch Hall, Schwäbisch Hall, Germany.

Jesco Pfitzenmaier (J)

Evangelisches Klinikum Bethel Johannesstift, Bielefeld, Germany.

Jan Fichtner (J)

Johanniter Krankenhaus Oberhausen, Oberhausen, Germany.

Andreas Neisius (A)

Barmherzige Brüder Trier, Trier, Germany.

Peter Hammerer (P)

Städtisches Klinikum Braunschweig, Brunswick, Germany.

Simone Wesselmann (S)

German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany.

Christoph Kowalski (C)

German Cancer Society, Kuno-Fischer-Strasse 8, Berlin, 14057, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH